COMPOSITIONS AND METHODS FOR FUMONISIN DETOXIFICATION

Abstract: Compositions and methods for the complete detoxification of fumonisin and fumonisin degradation products are provided. Particularly, nucleotide sequences corresponding to the detoxification enzymes are provided. The sequences find use in preparing expression cassettes for the transformation of a broad variety of host cells and organisms.

Description: COMPOSITIONS AND METHODS FOR FUMONISIN DETOXIFICATION FIELD OF THE INVENTION The invention relates to compositions and methods for detoxification or degradation of fumonisins and related toxins. The method has broad application in agricultural biotechnology and crop agriculture and in the improvement of food grain quality. BACKGROUND OF THE INVENTION Fungal diseases are common problems in crop agriculture. Many strides have been made against plant diseases as exemplified by the use of hybrid plants, pesticides, and improved agricultural practices. However, as any grower or home gardener can attest, the problems of fungal plant disease continue to cause difficulties in plant cultivation. Thus, there is a continuing need for new methods and materials for solving the problems caused by fungal diseases of plants. These problems can be met through a variety of approaches. For example, the infectious organisms can be controlled through the use of agents that are selectively biocidal for the pathogens. Another method is interference with the mechanism by which the pathogen invades the host crop plant. Yet another method, in the case of pathogens that cause crop losses, is interference with the mechanism by which the pathogen causes injury to the host crop plant. In the case of pathogens that produce toxins that are undesirable to mammals or other animals that feed on the crop plants, interference with toxin production, storage, or activity can be beneficial. Since their discovery and structural elucidation in 1988 (Bezuidenhout et al. (1988) Journal Chem. Soc, Chem. Commun. 1988:743-745), fumonisins have been recognized as a potentially serious problem in maize-fed livestock. They are linked to several animal toxicoses including leukoencephalomalacia (Marasas et al. (1988) Onderstepoort J. Vet. Res. 55:197-204; Wilson et al. (1990) American Association of Veterinary Laboratory Diagnosticians: Abstracts 33rd Annual Meeting, Denver, Colorado, Madison, Wisconsin, USA) and porcine pulmonary edema (Colvin et al . (1992) Mycopathologia 117:79- 82). Fumonisins are also suspected carcinogens (Geary et al. (1971) Coord. Chem. Rev. 7:81; Gelderblom et al. (1991) Carcinogenesis 72:1247-1251; Gelderblom et al. (1992) Carcinogenesis 73:433-437). Fusarium isolates in section Liseola produce fumonisins in culture at levels from 2 to > 4000 ppm (Leslie et al. (1992) Phytopathology 52:341-345). Isolates from maize (predominantly mating population A) are among the highest producers of fumonisin (Leslie et al., supra). Fumonisin levels detected in field-grown maize have fluctuated widely depending on location and growing season, but both preharvest and post-harvest surveys of field maize have indicated that the potential for high levels of fumonisins exists (Murphy et al. (1993) J. Agr. Food Chem. 41:261-266). Surveys of food and feed products have also detected fumonisin (Holcomb et al. (1993) J. Agr. Food Chem. ¥7:764-767; Hopmans et al. (1993) J Agr. Food Chem. ¥7:1655-1658); Sydenham et al. (1991) J Agr. Food Chem. 59:2014-2018). The etiology of Fusarium ear mold is poorly understood, although physical damage to the ear and certain environmental conditions can contribute to its occurrence (Nelson et al. (1992) Mycopathologia 777:29-36). Fusarium can be isolated from most field grown maize, even when no visible mold is present. The relationship between seedling infection and stalk and ear diseases caused by Fusarium is not clear. Genetic resistance to visible kernel mold has been identified (Gendloff et al. (1986) Phytopathology 7f5:684-688; Holley et al. (1989) Plant Dis. 73:578-580), but the relationship between visible mold and fumonisin production has yet to be elucidated. Fumonisins have been shown in in vitro mammalian cell studies to inhibit sphingolipid biosynthesis through inhibition of the enzyme sphingosine N-acetyl transferase, resulting in the accumulation of the precursor sphinganine (Norred et al. (1992) Mycopathologia 777:73-78; Wang et al. (1991) Biol. Chem. 266:14486; Yoo et al. (1992) Toxicol. Appl. Pharmacol. 114:9-15; Nelson et al. (1993) Annu. Rev. Phytpathol. 37:233-252). It is likely that inhibition of this pathway accounts for at least some of fumonisin's toxicity, and support for this comes from measures of sphinganine: sphingosine ratios in animals fed purified fumonisin (Wang et al. (1992) J. Nutr. 722:1706-1716). Fumonisins also affect plant cell growth (Abbas et al. (1992) Weed Technol. (5:548-552; Van Asch et al. (1992) Phytopathology 52:1330-1332; Vesonder et al. (1992) Arch. Environ. Contam. Toxicol. 23:464-467). Kuti et al. (1993) (Abstract, Annual Meeting American Phytopathological Society, Memphis, Tennessee: APS Press) reported on the ability of exogenously added fumonisins to accelerate disease development and increase sporulation of Fusarium moniliform and F. oxysporum on tomato. Enzymes that degrade the fungal toxin fumonisin to the compound API have been identified in U.S. Patent No. 5,716,820 and pending U.S. Patent Application Serial Nos. 08/888,949 and 08/888,950, both filed July 7, 1997, and hereby incorporated by reference. Plants expressing a fumonisin esterase enzyme, infected by fumonisin producing fungus, and tested for fumonisin and API were found to have low levels of fumonisin but high levels of API. API is less toxic than fumonisin to plants and probably also animals, but contamination with API is still a concern. The best result would be complete detoxification of fumonisin to a non-toxic form. Therefore additional enzymes capable of degrading fumonisin and fumonisin catabolic products are necessary for the complete detoxification of fumonisin. SUMMARY OF THE INVENTION A fumonisin detoxification gene cluster is provided. Particularly, the nucleotide sequence for the cluster from Bacterium 2412.1 (American Type Culture Collection Deposit Number 55552) is provided. At least twelve structural genes and three regulatory gene are provided. The sequences represent a catabolic pathway for fumonisins and fumonisin-like compounds. Compositions and methods for catabolism and detoxification of fumonisin, fumonisin-related toxins, and fumonisin-degradation products are provided. In particular, proteins involved in catabolism and transmembrane transport of fumonisin and fumonisin catabolic products are provided. Nucleotide sequences corresponding to the proteins are also included. The compositions are useful in the complete detoxification and degradation of fumonisin. The nucleotide sequences can be used in expression cassettes for transformation of host cells of interest. The compositions and methods of the invention provide a catabolic pathway for fumonisin. Thus, organisms can be genetically modified to provide for the complete catabolism and detoxification of fumonisin and fumonisin-related toxins. In particular, expression cassettes for expression of the sequences in plants and other organisms are provided as well as transformed plants and other host cells. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 sets forth the proposed pathway for fumonisin degradation by Bacterium 2412.1. Figure 2 illustrates the overlap of the individual lambda clones and cosmids which were sequenced to reconstruct the fumonisin catabolic gene cluster. Figure 3 provides a map of the open reading frames in the fumonisin catabolic gene cluster of bacterium 2412.1 Figure 4 schematically illustrates a plasmid vector comprising the gene for one of the fumonisin degradative enzymes of the invention operably linked to the ubiquitin promoter. DETAILED DESCRIPTION OF THE INVENTION A catabolic pathway for detoxification and degradation of fumonisin is provided. Particularly, enzymes involved in the degradation of fumonisin from Bacterium 2412.1 and nucleotide sequences encoding such enzymes are disclosed. Such enzymes and nucleotide sequences find use in the breakdown of fumonisin as well as fumonisin-degradation products. In this regard, enzymes can be synthesized and utilized or, alternatively, organisms can be transformed with the DNA sequences of the invention and used to detoxify fumonisin. A proposed pathway for the degradation of fumonisin by Bacterium 2412.1 is provided in Figure 1. The present invention provides enzymes and nucleotide sequences encoding the enzymes involved in this degradation pathway for fumonisin. In particular, the present invention provides for isolated nucleic acid molecules comprising the fumonisin catabolic gene cluster for Bacterium 2412.1 set forth in SEQ ID NO: 1, or the DNA sequences obtained from the overlapping clones deposited with the American Type Culture Collection and assigned Accession Numbers PTA-298, PTA-296, and PTA-297. By "DNA sequence obtained from the overlapping clones" is intended that the DNA sequence of the catabolic gene cluster can be obtained by sequencing 18 individual clones which together comprise the entire fumonisin catabolic cluster. Further provided are polypeptides having an amino acid sequence encoded by a nucleic acid molecule set forth in SEQ ID NO: 1, the nucleic acid molecule deposited as overlapping clones with the American Type Culture Collection and assigned Accession Numbers PTA-298, PTA-296, and PTA-297, and fragments and variants thereof. Eighteen plasmids containing overlapping clones were deposited with the American Type Culture Collection, Manassas, Virginia, and assigned Accession Numbers PTA-298, PTA-296, and PTA-297 (strain designations SuperCos_8.5_l, BAM_PL1, and BAM_PL2, respectively). It is noted, however, that the 18 clones contain common sequences at the regions where they overlap. One of skill in the art by sequencing the clones and aligning the overlap may obtain the entire sequence of the fumonisin catabolic gene cluster. These deposits will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. These deposits were made merely as a convenience for those of skill in the art and are not an admission that a deposit is required under 35 U.S.C. §112. In addition, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequences of a regulatory protein (fccJ) (SEQ ID NO: 21); a carboxylesterase (fccA) (SEQ ID NO: 3), a flavin monooxygenase (fccC) (SEQ ID NO: 7); an aldehyde dehydrogenase (fccD) (SEQ ID NO: 9); an alcohol dehydrogenase (fccE) (SEQ ID NO: 11); a permease (fed) (SEQ ID NO: 19); a CoA Ligase (fccF) (SEQ ID NO: 13); an acetohydroxyacid synthase (fccG) (SEQ ID NO: 15); a vitamin B12 transporter (fccH) (SEQ ID NO: 17); a citrate transport homolog (fccB) (SEQ ID NO: 5); a fumarate reductase (fccK) (SEQ ID NO: 23), a TonB dependent receptor (fccL) (SEQ ID NO: 25); a carbohydrate regulatory gene (fccO) (SEQ ID NO: 31); a citrate utilization B protein (fccN) (SEQ ID NO: 29); a possible flavoenzyme (fccP) (SEQ ID NO: 33); a leucine responsive regulatory protein (fccQ) (SEQ ID NO: 35); a possible N-methyl transferase (fccM) (SEQ ID NO: 27); fccR (SEQ ID NO: 37); fccS (SEQ ID NO: 39); and fccT (SEQ ID NO: 41). Further provided are polypeptides having an amino acid sequence encoded by a nucleic acid molecule described herein, for example those set forth in SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40. The nucleotide sequences of the invention can be used to isolate related sequences that are also encompassed by the present invention. The invention encompasses isolated or substantially purified nucleic acid or protein compositions. An "isolated" or "purified" nucleic acid molecule or protein, or biologically active portion thereof, is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. Preferably, an "isolated" nucleic acid is free of sequences (preferably protein encoding sequences) that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. A protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, 5%, (by dry weight) of contaminating protein. When the protein of the invention or biologically active portion thereof is recombinantly produced, preferably culture medium represents less than about 30%, 20%, 10%, or 5% (by dry weight) of chemical precursors or non-protein-of-interest chemicals. The isolated material optionally comprises material not found with the material in its natural environment or, if the material is in its natural environment, the material has been synthetically (non-naturally) altered by deliberate human intervention to a composition and/or placed at a locus in the cell (e.g., genome or subcellular organelle) not native to a material found in that environment. The alteration to yield the synthetic material can be performed on the material within or removed from its natural state. For example, a naturally occurring nucleic acid becomes an isolated nucleic acid if it is altered, or if it is transcribed from DNA that has been altered, by non-natural, synthetic (i.e., "man-made") methods performed within the cell from which it originates. See, e.g., Compounds and Methods for Site Directed Mutagenesis in Eukaryotic Cells, Kmiec, U.S. Patent No. 5,565,350; In vivo Homologous Sequence Targeting in Eukaryotic Cells; Zarling et al, PCT/US93/03868. Likewise, a naturally occurring nucleic acid (e.g., a promoter) becomes isolated if it is introduced by non-naturally occurring means to a locus of the genome not native to that nucleic acid. Nucleic acids that are "isolated" as defined herein are also referred to as "heterologous" nucleic acids. A carboxylesterase and amine oxidase from Exophiala spinifera have been previously described in U.S. Patent No. 5,716,820 and pending U.S. Patent Application Serial Nos. 08/888,949 and 08/888,950. Such disclosures are herein incorporated by reference. The sequences of the invention can be used in combination with those previously disclosed in U.S. provisional application numbers 60/092,936 and 60/135,391 herein incorporated by reference. The enzymes and nucleotide sequences of the present invention provide a means for catabolism of fumonisin and of the fumonisin-degradation products. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of botany, microbiology, tissue culture, molecular biology, chemistry, biochemistry, and recombinant DNA technology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Langenheim and Thimann (1982) Botany: Plant Biology and Its Relation to Human Affairs (John Wiley); Vasil, ed. (1984) Cell Culture and Somatic Cell Genetics of Plants, Vol. 1; Stanier et al. (1986) The Microbial World (5th ed., Prentice-Hall); Dhringra and Sinclair (1985) Basic Plant Pathology Methods (CRC Press); Maniatis et al. (1982) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York); Glover, ed. (1985) DNA Cloning, Vols. I and II; Gait, ed. (1984) Oligonucleotide Synthesis; Hames and Higgins, eds. (1984) Nucleic Acid Hybridization; and the series Methods in Enzymology (Colowick and Kaplan, eds., Academic Press, Inc.). In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below. By "microbe" is meant any microorganism (including both eukaryotic and prokaryotic microorganisms), such as fungi, yeast, bacteria, actinomycetes, algae, and protozoa, as well as other unicellular structures. A "fumonisin-producing microbe" is any microbe capable of producing the mycotoxin fumonisin or analogues thereof. Such microbes are generally members of the fungal genus Fusarium, as well as recombinantly derived organisms that have been genetically altered to enable them to produce fumonisin or analogues thereof. By "degrading or catabolizing fumonisin" is meant any modification to the fumonisin or API molecule that causes a decrease or loss in its toxic activity. Such a change can comprise cleavage of any of the various bonds, oxidation, reduction, the addition or deletion of a chemical moiety, or any other change that affects the activity of the molecule. In a preferred embodiment, the modification includes hydrolysis of the two ester linkages in the molecule as a first step and then oxidative deamination. Furthermore, chemically altered fumonisin can be isolated from cultures of microbes that produce an enzyme of this invention, such as by growing the organisms in media containing radioactively-labeled fumonisin, tracing the label, and isolating the degraded toxin for further study. The degraded fumonisin can be compared to the active compound for its phytotoxicity or mammalian toxicity in known sensitive species, such as porcines and equines. Such toxicity assays are known in the art. For example, in plants a whole leaf bioassay can be used in which solutions of the active and inactive compound are applied to the leaves of sensitive plants. The leaves may be treated in situ or, alternatively, excised leaves may be used. The relative toxicity of the compounds can be estimated by grading the ensuing damage to the plant tissues and by measuring the size of lesions formed within a given time period. Other known assays can be performed at the cellular level, employing standard tissue culture methodologies e.g., using cell suspension cultures. For purposes of the invention, the fumonisin or fumonisin degradation products will be degraded to at least about 50% to about 10% or less of the original toxicity, preferably about 30% to about 5% or less, more preferably about 20% to about 1% or less. By "fumonisin esterase" is meant any enzyme capable of hydrolysis of the ester linkages in fumonisin. Two examples of such enzymes are ESP1 and BEST1 found in U.S. Patent Application No. 5,716,820 and pending U.S. Application Nos. 08/888,949 and 08/888,950, both filed July 7, 1997. By "structurally related mycotoxin" is meant any mycotoxin having a chemical structure related to a fumonisin such as fumonisin Bl, for example AAL toxin, fumonisin B2, fumonisin B3, fumonisin B4, fumonisin CI, fumonisin Al and A2, and their analogues, as well as other mycotoxins having similar chemical structures that would be expected to be detoxified by activity of the fumonisin degradative enzymes elaborated by Exophiala spinifera, American Type Culture Collection Accession No. 74269, Rhinocladiella atrovirens, American Type Culture Collection Accession No. 74270, or the bacterium of American Type Culture Collection Accession No. 55552. By "amplified" is meant the construction of multiple copies of a nucleic acid sequence or multiple copies complementary to the nucleic acid sequence using at least one of the nucleic acid sequences as a template. Amplification systems include the polymerase chain reaction (PCR) system, ligase chain reaction (LCR) system, nucleic acid sequence based amplification (NASBA, Cangene, Mississauga, Ontario), Q-Beta Replicase systems, transcription-based amplification system (TAS), and strand displacement amplification (SDA). See, e.g., Persing et al, ed. (1993) Diagnostic Molecular Microbiology: Principles and Applications, (American Society for Microbiology, Washington, D.C.). The product of amplification is termed an amplicon. Fragments and variants of the disclosed nucleotide sequences and proteins encoded thereby are also encompassed by the present invention. By "fragment" is intended a portion of the nucleotide sequence or a portion of the amino acid sequence and hence protein encoded thereby. Fragments of a nucleotide sequence may encode protein fragments that retain the biological activity of the native protein and hence degrade or catabolize fumonisin. Alternatively, fragments of a nucleotide sequence that are useful as hybridization probes generally do not encode protein fragments retaining biological activity. Thus, fragments of a nucleotide sequence may range from at least about 20 nucleotides, about 50 nucleotides, about 100 nucleotides, and up to the full-length nucleotide sequence encoding the proteins of the invention. A fragment of a fumonisin-degrading nucleotide sequence that encodes a biologically active portion of a fumonisin-degrading protein of the invention will encode at least 15, 20, 25, 30, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, or 950 contiguous amino acids, or up to the total number of amino acids present in a full-length fumonisin- degrading protein of the invention. By fragment it is also intended any nucleotide sequence of the fumonisin-catabolic gene cluster that encodes a biologically active portion of a fumonisin-degrading protein. Fragments of a fumonisin-degrading nucleotide sequence that are useful as hybridization probes for PCR primers generally need not encode a biologically active portion of a fumonisin-degrading protein. Thus, a fragment of a fumonisin-degrading nucleotide sequence or a fragment of the fumonisin-catabolic gene cluster may encode a biologically active portion of a fumonisin-degrading protein or it may be a fragment that can be used as a hybridization probe or PCR primer using methods disclosed below. A biologically active portion of a fumonisin-degrading protein can be prepared by isolating a portion of one of the fumonisin-degrading nucleotide sequences or a portion of the fumonisin-catabolic gene cluster of the invention, expressing the encoded portion of the fumonisin-degrading protein (e.g., by recombinant expression in vitro), and assessing the activity of the encoded portion of the fumonisin-degrading protein. Nucleic acid molecules that are fragments of a fumonisin-degrading nucleotide sequence comprise at least 15, 20, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800 nucleotides, or up to the number of nucleotides present in a fumonisin-degrading nucleotide sequence or up to the number of nucleotides present in the full-length fumonisin catabolic gene cluster disclosed herein. By "variants" is intended substantially similar sequences. For nucleotide sequences conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the fumonisin-degrading polypeptides of the invention. Naturally occurring allelic variants such as these can be identified with the use of well-known molecular biology techniques, as, for example, with polymerase chain reaction (PCR) and hybridization techniques as outlined below. Variant nucleotide sequences also include synthetically derived nucleotide sequences, such as those generated, for example, by using site-directed mutagenesis but which still encode a fumonisin- degrading protein of the invention. Generally, nucleotide sequence variants of the invention will have at least 40%, 50%, 60%, 70%, generally, 80%, preferably 85%, 90%, up to 95%, 98% sequence identity to its respective native nucleotide sequence. By "variant" protein is intended a protein derived from the native protein by deletion (so-called truncation) or addition of one or more amino acids to the N-terminal and/or C-terminal end of the native protein; deletion or addition of one or more amino acids at one or more sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein. Such variants may result from, for example, genetic polymorphism or from human manipulation. The proteins of the invention may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants of the fumonisin-degrading proteins can be prepared by mutations in the DNA. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Kunkel (1985) Proc. Natl. Acad. Sci. USA 82:488-492; Kunkel et al. (1987) Methods in Enzymol. 154:367-382; US Patent No. 4,873,192; Walker and Gaastra, eds. (1983) Techniques in Molecular Biology (MacMillan Publishing Company, New York) and the references cited therein. Guidance as to appropriate amino acid substitutions that do not affect biological activity of the protein of interest may be found in the model of Dayhoff et al. (1978) Atlas of Protein Sequence and Structure (Natl. Biomed. Res. Found., Washington, D.C.), herein incorporated by reference. Conservative substitutions, such as exchanging one amino acid with another having similar properties, may be preferred. Thus, the genes and nucleotide sequences of the invention include both the naturally occurring sequences as well as mutant forms. Likewise, the proteins of the invention encompass both naturally occurring proteins as well as variations and modified forms thereof. Such variants will continue to possess the desired ability to degrade fumonisin and fumonisin-like compounds. Obviously, the mutations that will be made in the DNA encoding the variant must not place the sequence out of the reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. See, EP Patent Application Publication No. 75,444. The deletions, insertions, and substitutions of the protein sequences encompassed herein are not expected to produce radical changes in the characteristics of the protein. However, when it is difficult to predict the exact effect of the substitution, deletion, or insertion in advance of doing so, one skilled in the art will appreciate that the effect will be evaluated by routine screening assays. That is, the activity can be evaluated by a decrease or loss in the toxic activity of fumonisin or AP 1. Variant nucleotide sequences and proteins also encompass sequences and proteins derived from a mutagenic and recombinogenic procedure such as DNA shuffling. With such a procedure, one or more different fumonisin- degrading protein coding sequences can be manipulated to create a new fumonisin-degrading protein possessing the desired properties. In this manner, libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides comprising sequence regions that have substantial sequence identity and can be homologously recombined in vitro or in vivo. For example, using this approach, sequence motifs encoding a domain of interest may be shuffled between the fumonisin-degrading genes of the invention and other known fumonisin-degrading genes to obtain a new gene coding for a protein with an improved property of interest, such as an increased K m in the case of an enzyme. Strategies for such DNA shuffling are known in the art. See, for example, Stemmer (1994) Proc. Natl. Acad. Sci. USA 91 :10747-10751; Stemmer (1994) Nature 370:389-391; Crameri et α/. (1997) Nature Biotech. 15:436-438; Moore et al. (1997) J. Mol. Biol. 272:336-347; Zhang et al. (1997) Proc. Natl. Acad. Sci. USA 94:4504-4509; Crameri et al. (1998) Nature 391:288-291; and U.S. Patent Nos. 5,605,793 and 5,837,458. When the nucleic acid is prepared or altered synthetically, advantage can be taken of known codon preferences of the intended host where the nucleic acid is to be expressed. For example, although nucleic acid sequences of the present invention may be expressed in both monocotyledonous and dicotyledonous plant species, sequences can be modified to account for the specific codon preferences and GC content preferences of monocotyledonous plants or dicotyledonous plants as these preferences have been shown to differ (Murray et al. (1989) Nucl. Acids Res. 77:477-498). Thus, the maize preferred codon for a particular amino acid may be derived from known gene sequences from maize. Maize codon usage for 28 genes from maize plants are listed in Table 4 of Murray et al., supra. As used herein, "heterologous" in reference to a nucleic acid is a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention. For example, a promoter operably linked to a heterologous structural gene is from a species different from that from which the structural gene was derived, or, if from the same species, one or both are substantially modified from their original form. A heterologous protein may originate from a foreign species or, if from the same species, is substantially modified from its original form by deliberate human intervention. By "host cell" is meant a cell that contains a vector and supports the replication and/or expression of the expression vector. Host cells may be prokaryotic cells such as E. coli, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells. Preferably, host cells are monocotyledonous or dicotyledonous plant cells, including but not limited to maize, sorghum, sunflower, soybean, wheat, alfalfa, rice, cotton, and tomato. A particularly preferred monocotyledonous host cell is a maize host cell. The term "hybridization complex" includes reference to a duplex nucleic acid structure formed by two single-stranded nucleic acid sequences selectively hybridized with each other. As used herein, "operably linked" includes reference to a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame. As used herein, "polynucleotide" includes reference to a deoxyribopolynucleotide, ribopolynucleotide, or analogues thereof that have the essential nature of a natural ribonucleotide in that they hybridize, under stringent hybridization conditions, to substantially the same nucleotide sequence as naturally occurring nucleotides and/or allow translation into the same amino acid(s) as the naturally occurring nucleotide(s). A polynucleotide can be full- length or a subsequence of a native or heterologous structural or regulatory gene. Unless otherwise indicated, the term includes reference to the specified sequence as well as the complementary sequence thereof. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term polynucleotide as it is employed herein embraces such chemically, enzymatically, or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including ter alia, simple and complex cells. As used herein, "promoter" includes reference to a region of DNA upstream from the start of transcription and involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A "plant promoter" is a promoter capable of initiating transcription in plant cells. Exemplary plant promoters include, but are not limited to, those that are obtained from plants, plant viruses, and bacteria that comprise genes expressed in plant cells, such as Agrobacterium or Rhizobium. Examples are promoters that preferentially initiate transcription in certain tissues, such as leaves, roots, seeds, fibers, xylem vessels, tracheids, or sclerenchyma. Such promoters are referred to as "tissue preferred". A "cell type" specific promoter primarily drives expression in certain cell types in one or more organs, for example, vascular cells in roots or leaves. An "inducible" promoter is a promoter that is under environmental control. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions or the presence of light. Another type of promoter is a developmentally regulated promoter. For example, a promoter that drives expression during pollen development. Tissue-preferred, cell type specific, developmentally regulated, and inducible promoters constitute the class of "non-constitutive" promoters. A "constitutive" promoter is a promoter that is active under most environmental conditions. Constitutive promoters are known in the art and include, for example, 35S promoter (Meyer et al. (1997) J Gen. Virol. 75:3147-3151); ubiquitin; as well as those disclosed in U.S. Patent Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680; 5,268,463; 5,608,142. As used herein, "recombinant" includes reference to a cell or vector that has been modified by the introduction of a heterologous nucleic acid or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found in identical form within the native (non- recombinant) form of the cell or express native genes that are otherwise abnormally expressed, underexpressed, or not expressed at all as a result of deliberate human intervention. The term "recombinant" as used herein does not encompass the alteration of the cell or vector by naturally occurring events (e.g., spontaneous mutation, natural transformation/transduction/transposition) such as those occurring without deliberate human intervention. As used herein, a "recombinant expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a target cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid to be transcribed, and a promoter. The term "selectively hybridizes" includes reference to hybridization, under stringent hybridization conditions, of a nucleic acid sequence to a specified nucleic acid target sequence to a detectably greater degree (e.g., at least 2-fold over background) than its hybridization to non-target nucleic acid sequences and to the substantial exclusion of non-target nucleic acids. Selectively hybridizing sequences typically have about at least 40 to 80% sequence identity, preferably 90%> sequence identity, and most preferably 100% sequence identity (i.e., complementary) with each other. The nucleotide sequences of the invention can be used to isolate corresponding sequences from other organisms. In this manner, methods such as PCR, hybridization, and the like can be used to identify such sequences based on their sequence homology to the sequences set forth herein. Sequences isolated based on their sequence identity to the entire fumonisin-degrading coding sequences or to the catabolic gene cluster sequence set forth herein or to fragments thereof are encompassed by the present invention. In a PCR approach, oligonucleotide primers can be designed for use in PCR reactions to amplify corresponding DNA sequences from cDNA or genomic DNA extracted from any organism of interest. Methods for designing PCR primers and PCR cloning are generally known in the art and are disclosed in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York). See also Innis et al., eds. (1990) PCR Protocols: A Guide to Methods and Applications (Academic Press, New York); Innis and Gelfand, eds. (1995) PCR Strategies (Academic Press, New York); and Innis and Gelfand, eds. (1999) PCR Methods Manual (Academic Press, New York). Known methods of PCR include, but are not limited to, methods using paired primers, nested primers, single specific primers, degenerate primers, gene-specific primers, vector-specific primers, partially-mismatched primers, and the like. In hybridization techniques, all or part of a known nucleotide sequence is used as a probe that selectively hybridizes to other corresponding nucleotide sequences present in a population of cloned genomic DNA fragments or cDNA fragments (i.e., genomic or cDNA libraries) from a chosen organism. The hybridization probes may be genomic DNA fragments, cDNA fragments, RNA fragments, or other oligonucleotides, and may be labeled with a detectable group such as 32 P, or any other detectable marker. Thus, for example, probes for hybridization can be made by labeling synthetic oligonucleotides based on the fumonisin-degrading coding sequences of the invention. Methods for preparation of probes for hybridization and for construction of cDNA and genomic libraries are generally known in the art and are disclosed in Sambrook et al . (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York). For example, an entire fumonisin-degrading nucleotide sequence or the entire fumonisin catabolic gene cluster sequence disclosed herein, or one or more portions thereof, may be used as a probe capable of specifically hybridizing to corresponding fumonisin-degrading sequences and messenger RNAs. To achieve specific hybridization under a variety of conditions, such probes include sequences that are unique among fumonisin-degrading sequences and are preferably at least about 10 nucleotides in length, and most preferably at least about 20 nucleotides in length. Such probes may be used to amplify corresponding fumonisin-degrading sequences from a chosen organism by PCR. This technique may be used to isolate additional coding sequences from a desired plant organism or as a diagnostic assay to determine the presence of coding sequences in a plant an organism. Hybridization techniques include hybridization screening of plated DNA libraries (either plaques or colonies; see, for example, Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York). Hybridization of such sequences may be carried out under stringent conditions. By "stringent conditions" or "stringent hybridization conditions" is intended conditions under which a probe will hybridize to its target sequence to a detectably greater degree than to other sequences (e.g., at least 2-fold over background). Stringent conditions are sequence-dependent and will be different in different circumstances. By controlling the stringency of the hybridization and/or washing conditions, target sequences that are 100%) complementary to the probe can be identified (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected (heterologous probing). Generally, a probe is less than about 1000 nucleotides in length, preferably less than 500 nucleotides in length. Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35%> formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37°C, and a wash in IX to 2X SSC (20X SSC = 3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55 ° C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1.0 M NaCl, 1% SDS at 37°C, and a wash in 0.5X to IX SSC at 55 to 60°C. Exemplary high stringency conditions include hybridization in 50%) formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.1X SSC at 60 to 65°C. Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, the T m can be approximated from the equation of Meinkoth and Wahl (1984) Anal. Biochem. 735:267-284: T m = 81.5°C + 16.6 (log M) + 0.41 (%GC) - 0.61 (% form) - 500/L; where M is the molarity of monovalent cations, %GC is the percentage of guanosine and cytosine nucleotides in the DNA, %> form is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. The T m is the temperature (under defined ionic strength and pH) at which 50%> of a complementary target sequence hybridizes to a perfectly matched probe. T m is reduced by about 1 °C for each 1%> of mismatching; thus, T m , hybridization, and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example, if sequences with >90% identity are sought, the T m can be decreased 10°C. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T m ) for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4°C lower than the thermal melting point (T m ); moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10°C lower than the thermal melting point (T m ); low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15, or 20°C lower than the thermal melting point (T m ). Using the equation, hybridization and wash compositions, and desired T m , those of ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in a T m of less than 45°C (aqueous solution) or 32°C (formamide solution), it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology — Hybridization with Nucleic Acid Probes, Part I, Chapter 2 (Elsevier, New York); and Ausubel et al, eds. (1995) Current Protocols in Molecular Biology, Chapter 2 (Greene Publishing and Wiley- Interscience, New York). See Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York). In general, sequences that encode for a fumonisin-degrading protein and hybridize to the fumonisin-degrading sequences or the sequences of the fumonisin catabolic gene cluster disclosed herein will be at least 40%> to 50% homologous, about 60% to 70%) homologous, and even about 80%, 85%o, 90%>, 95%o to 98%o homologous or more with the disclosed sequences. That is, the sequence similarity of sequences may range, sharing at least about 40% to 50%, about 60% to 70%, and even about 80%, 85%, 90%, 95% to 98% sequence similarity. The following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: (a) "reference sequence", (b) "comparison window", (c) "sequence identity", (d) "percentage of sequence identity", and (e) "substantial identity". (a) As used herein, "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence. (b) As used herein, "comparison window" makes reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Generally, the comparison window is at least 20 contiguous nucleotides in length, and optionally can be 30, 40, 50, 100, or longer. Those of skill in the art understand that to avoid a high similarity to a reference sequence due to inclusion of gaps in the polynucleotide sequence a gap penalty is typically introduced and is subtracted from the number of matches. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith et al. (\9 \) Adv. Appl Math. 2:482; by the homology alignment algorithm of Needleman et al. (1970) J. Mol. Biol. 48:443; by the search for similarity method of Pearson et al. (1988) Proc. Natl. Acad. Sci. 55:2444; by computerized implementations of these algorithms, including, but not limited to: CLUSTAL in the PC/Gene program by Intelligenetics, Mountain View, California; GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Drive, Madison, Wisconsin, USA; the CLUSTAL program is well described by Higgins et al. (1988) Gene 73:237-244 (1988); Higgins et al. (1989) CABIOS 5:151-153; Corpet et α/. (1988) Nucleic Acids Res. 7(5:10881-90; Huang et al. (1992) Computer Applications in the Biosciences 5:155-65, and Person et al. (1994) Meth. Mol. Biol. 24:307-331; preferred computer alignment methods also include the BLASTP, BLASTN, and BLASTX algorithms (see Altschul et al. (1990) J Mol. Biol. 275:403-410). Alignment is also often performed by inspection and manual alignment. (c) As used herein, "sequence identity" or "identity" in the context of two nucleic acid or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have "sequence similarity" or "similarity". Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California). (d) As used herein, "percentage of sequence identity" means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity. (e)(i) The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70% sequence identity, preferably at least 80%>, more preferably at least 90%>, and most preferably at least 95%, compared to a reference sequence using one of the alignment programs described using standard parameters. One of skill in the art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning, and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 60%>, more preferably at least 70%, 80%, 90%, and most preferably at least 95%. Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH. However, stringent conditions encompass temperatures in the range of about 1°C to about 20°C, depending upon the desired degree of stringency as otherwise qualified herein. Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. One indication that two nucleic acid sequences are substantially identical is when the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid. (e)(ii) The term "substantial identity" in the context of a peptide indicates that a peptide comprises a sequence with at least 70%) sequence identity to a reference sequence, preferably 80%, more preferably 85%>, most preferably at least 90%) or 95%) sequence identity to the reference sequence over a specified comparison window. Preferably, optimal alignment is conducted using the homology alignment algorithm of Needleman et al. (1970) J. Mol. Biol. ¥5:443. An indication that two peptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution. Peptides that are "substantially similar" share sequences as noted above except that residue positions that are not identical may differ by conservative amino acid changes. As indicated, the enzymes and nucleotide sequences encoding such enzymes are involved in the degradation of fumonisin and fumonisin-like compounds. Such enzymes and nucleotide sequences can be utilized alone or in combination to engineer microbes or other organisms to completely metabolize fumonisin and resist its toxic effects. That is, at least one of the genes of the invention can be used to transform a host cell of interest. Alternatively, the entire fumonisin catabolic cluster can be cloned into the host cell. Methods for cloning gene clusters into a plasmid, a cosmid or a Bac are known in the art. The cloned cluster can then be moved to the host cell of interest, generally another microorganism or yeast cell. Under suitable induction conditions, the pathway will be activated and fumonisin degraded. See, for example, Prieto et al. (1996) J. Bacteriol 75(7): 111-120, herein incorporated by reference. Fumonisin is produced in the intercellular spaces (apoplast) of Fusarium-in&cted maize cells. Thus, the apoplast is the preferred location for esterase and possibly other catabolic enzymes. It is possible that some fumonisin could diffuse or be transported into the maize cells before it is broken down by the apoplastic enzymes and may escape catabolism. Thus, it may be beneficial to express a fumonisin pump in such cells. In this manner, any fumonisin entering the cell will be pumped out and reexposed to catabolic enzymes. Similar toxin pumps exist in other toxin-producing fungi that show resistance to toxins or antibiotics. The enzymes from Bacterium 2412.1 involved in the degradation of fumonisin are provided in Table 1. Additionally, they are discussed briefly below. TABLE 1 fee A Esterase: This esterase, also known as BacEst, was previously shown to hydrolyze the tricarballylate esters of fumonisins. This enzyme is the bacterial homolog of the Exophiala spinifera esterase, ESP1. fccB Citrate/Tricarballylate Transport Protein: This protein may be necessary to break down the tricarballylic acid resulting from hydrolysis of fumonisin by the esterase. The citrate/tricarballylate transporter can be used to transport the tricarballylic acid into the cell where it may be able to be broken down by endogenous enzymes. Additional enzymes that may be discovered could be used as well to effect the removal of tricarballylate once it is in the cell. fccC Flavin Monooxygenase: This enzyme has homology to monooxygnease that act on keto or quinone groups, oxidizing them to a carboxylate with carbon chain breakage. In our detoxification strategy, it may be necessary to provide more complete catabolism of fumonisin in transgenic maize or other transgenic organisms than can be provided by esterase and deaminase enzymes. If so, the monooxygenase activity of this clone is predicted to result in the oxidation of 2-OP to a compound that would lack a keto group, having instead a terminal aldehyde group, or possibly a carboxylate group. This is due to a type of enzymatic oxidation referred to as Baeyer-Villiger oxidation, in which monooxygen is inserted adjacent to a keto function, resulting in a lactone or ester linkage (Walsch & Chen, Angew. Chem. Int Ed. Engl 27 (1988) 333-343). The metabolism of trans-cyclohexane-1,2 diol by Acinetobacter provides a model for the activity of a Baeyer- Villiger monooxygenase on 2-OP (Davey & Trudgill, 1977, Eur. J. Biochem 74:115-127). This diol is first oxidized to ortho hydroxy cyclohexanone by a different enzyme, and then a monooxygen is inserted between the quione and hydroxy functions by the Baeyer- Villiger enzyme, cyclohexanone monooxygenase . This intermediate spontaneously rearranges to a linear aldehyde carboxylic acid. By analogy, for 2-OP we would predict insertion of oxygen between carbons 2 and 3 and then spontaneous cleavage to a C22 aldehyde and acetic acid. Further oxidation by an aldehyde dehydrogenase would convert this compound to a carboxylic acid; other transformations would also be possible given the high reactivity of the aldehyde group. fccD Aldehyde Dehydrogenase: One likely product of flavin monooxygenase oxidation of 2-OP is a C- 20 aldehyde (see above); if so, we would predict that an aldehyde dehyrogenase would be available to oxidize the aldehyde to a carboxylate group, as a prerequisite to insertion into the beta-oxidation pathway for catabolism to acetyl co-A. fccE Alcohol Dehydrogenase: This gene shows homology to members of the short-chain dehydrogenase (SD) class of oxidoreductases, designated in Prosite as group PSO-00060. This class contains many NADP or NAD+ requiring alcohol dehydrogenases as well as anabolic enzymes that convert 2-keto Co-A acid esters to -corresponding alcohols. This enzyme may be responsible for oxidation of the C-5, alcohol of the carboxylate to a keto group, which would result in an alpha keto acid that could be further degraded by beta-oxidation. The enzyme could also oxidize hydroxyls at C13 and C14 to ketones, allowing a monooxygenase such as that described above to further oxidize and fragment the carbon chain. It is also possible that this enzyme attacks the C5 hydroxyl of API . Since the C-5 hydroxyl group of API is considered important for toxicity, this enzyme may be useful in detoxification of API. fccF Co A Ligase: This enzyme may provide conjugation of a fumonisin-derived carboxylic acid with coenzyme A, prior to beta-oxidation. fccG Acetohydroxy acid Synthase: This gene may code for a protein that provides a pH stat when fumonisin metabolites are being metabolized. fccH Vitamin B12 Receptor: This receptor possibly plays a role in membrane transport of breakdown products or import of cofactors needed for enzymes in the pathway. feel Permease: This protein is expected to have a role in the transport of metabolites into the cells, or exclusion of fumonisin. fccJ Regulatory Protein: Similar to LysR regulatory protein from E. coli, this protein probably functions to suppress transcription of pathway genes until the appropriate stimulus (i.e., fumonisin or API or TCA) is present. fccK Fumarte Reductase (Aspartate Oxidase): This gene encodes a redox enzyme homolog that may oxidize the C-2 amine of API and/or fumonisin. fccL TonB Dependent Receptor: This protein is involved in iron uptake. FccM: This protein has homology to an N-methyl transf erase and may be involved in antibiotic resistance. In addition, it may also function in methylating FBI or API to reduce toxicity. FccN: The fccN gene encodes a citrate utilization B protein. FccO Carbohydrate Regulatory Protein: This protein may be involved in the regulation of carbohydrate pathways. It may also down-regulate genes for non-fumonisin catabolysis or may be involved in regulating gene expression in the fumonisin cluster. FccP: This gene is contained within the antisense strand of feel and may encode a flavoenzyme. The protein may be an API /FBI deaminating enzyme based on similarity to flavoenzymes which include amine oxidases. FccQ Leucine Responsive Regulatory Protein: This protein may be involved in regulation of catabolic gene expression. FccR, FccS, FccT: These proteins show no significant homology to other known proteins. Compositions of the invention include the native nucleotide sequences for the catabolic genes, as well as variants and modifications thereof. It is recognized that having elucidated the pathway for fumonisin catabolism in Bacterium 2412.1, such DNA sequences can be inserted into expression cassettes and used to transform a variety of organisms. Enzymes produced recombinantly may be tested for their ability to modify fumonisin, fumonisin- related toxins, or a fumonisin byproduct using labeled starting material and appropriate buffer and cofactor conditions. For example, to test aldehyde dehydrogenase activity, the aldehyde dehydrogenase produced in a recombinant manner would be incubated with cofactors, NAD+ or NADP+, and 14 C-labeled 2-OP for various times and then an aliquot of the reaction mix spotted on TLC. Enzyme activity would be indicated by the appearance of a new radiolabeled spot at a different Rf on the TLC plate. Compositions of the invention include the native nucleotide sequences for the catabolic genes and the fumonisin gene cluster, as well as variants and modifications thereof. Particularly, the nucleotide sequences, or fragments thereof, of SEQ ID NOS: 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 and 40 can be utilized to isolate and/or synthesize full-length DNA sequences. Methods are known in the art for cloning of full-length cDNAs. Such techniques include, for example, RACE-PCR using oligonucleotide primers based on the known sequence, or cDNA library screening with labeled cDNA as probe, or by means of PCR of genomic DNA using a gene-specific probe and end-ligated primers (e.g., Genome Walker™ Clontech). It is recognized that having elucidated the pathway for fumonisin catabolism in Exophiala, such DNA sequences can be inserted into expression cassettes and used to transform a variety of organisms. Enzymes produced recombinantly may be tested for their ability to modify fumonisin or a fumonisin byproduct using labeled starting material and appropriate buffer and cofactor conditions. For example, to test aldehyde dehydrogenase activity, the aldehyde dehydrogenase produced in a recombinant manner would be incubated with cofactors, NAD+ or NADP, and 14 C -labeled 2-OP for various times and then an aliquot of the reaction mix spotted on TLC. Enzyme activity would be indicated by the appearance of a new radiolabeled spot at a different Rf on the TLC plate. The sequences of the invention can be introduced into any host organism. The sequences to be introduced may be used in expression cassettes for expression in the host of interest where expression in the host is necessary for transcription. One of skill would recognize that modifications can be made to a protein of the present invention without diminishing its biological activity. Some modifications may be made to facilitate the cloning, expression, or incorporation of the targeting molecule into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (e.g., poly His) placed on either terminus to create conveniently located restriction sites or termination codons or purification sequences. Where expression cassettes are needed, such expression cassettes will comprise a transcriptional initiation region linked to the coding sequence or antisense sequence of the nucleotide of interest. Such an expression cassette is provided with a plurality of restriction sites for insertion of the sequence to be under the transcriptional regulation of the regulatory regions. The expression cassette may additionally contain selectable marker genes. The marker gene confers a selectable phenotype on the transformed cells. Usually, the selectable marker gene will encode antibiotic resistance, with suitable genes including genes coding for resistance to the antibiotic spectinomycin (e.g. , the aada gene), the streptomycin phosphotransf erase (SPT) gene coding for streptomycin resistance, the neomycin phosphotransferase (NPTII) gene encoding kanamycin or geneticin resistance; the hygromycin phosphotransferase (HPT) gene coding for hygromycin resistance, genes coding for resistance to herbicides which act to inhibit the action of acetolactate synthase (ALS), in particular the sulfonylurea-type herbicides (e.g. , the acetolactate synthase (ALS) gene containing mutations leading to such resistance in particular the S4 and/or Hra mutations), genes coding for resistance to herbicides which act to inhibit action of glutamine synthase, such as phosphinothricin or basta (e.g., the bar gene), or other such genes known in the art. The bar gene encodes resistance to the herbicide basta, and the ALS gene encodes resistance to the herbicide chlorsulfuron. The transcriptional initiation region, the promoter, may be native or analogous or foreign or heterologous to the host as well as to the coding sequence. Additionally, the promoter may be the natural sequence or alternatively a synthetic sequence. By foreign it is intended that the transcriptional initiation region is not found in the native plant into which the transcriptional initiation region is introduced. As used herein a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence. The transcriptional cassette will include in the 5'-to-3' direction of transcription, a transcriptional and translational initiation region, a DNA sequence of interest, and a transcriptional and translational termination region functional in the host. The termination region may be native with the transcriptional initiation region, may be native with the DNA sequence of interest, or may be derived from another source. For use in plants or plant cells, convenient termination regions are available from the Ti-plasmid of A. tumefaciens, such as the octopine synthase and nopaline synthase termination regions. See also Guerineau et «/. (1991) Mol. Gen. Genet. 262:141-144; Proudfoot (1991) Cell 64:671-674; Sanfacon et al. (1991) Genes Dev. 5:141- 149; Mogen et al. (1990) Plant Cell 2:1261-1272; Munroe et al. (1990) Gene 97:151-158; Ballas et al (1989) Nucleic Acids Res. 77:7891-7903; Joshi et al. (1987) Nucleic Acids Res. 15:9627-9639. Nucleotide sequences of the invention are provided in expression cassettes for expression in the host cell of interest. The cassette will include 5' and 3' regulatory sequences operably linked to the sequence of interest. The cassette may additionally contain at least one additional sequence to be cotransformed into the organism. Alternatively, the additional sequence(s) can be provided on another expression cassette. Where appropriate, the gene(s) may be optimized for increased expression in the transformed plant. That is, the genes can be synthesized using plant-preferred codons for improved expression. Methods are available in the art for synthesizing plant-preferred genes. See, for example, U.S. Patent Nos. 5,380,831, 5,436,391, and Murray et al. (1989) Nucleic Acids Res. 77:477-498, herein incorporated by reference. Additional sequence modifications are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well-characterized sequences that may be deleterious to gene expression. The G-C content of the sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures. The expression cassettes may additionally contain 5' leader sequences in the expression cassette construct. Such leader sequences can act to enhance translation. Translation leaders are known in the art and include: picornavirus leaders, for example, EMCV leader (Encephalomyocarditis 5' noncoding region) (Elroy-Stein et al. (1989) PNAS USA 5f5:6126-6130); potyvirus leaders, for example, TEV leader (Tobacco Etch Virus) (Allison et al (1986); MDMV leader (Maize Dwarf Mosaic Virus); Virology 154:9-20), and human immunoglobulin heavy-chain binding protein (BiP), (Macejak et al. (1991) Nature 353:90-94); untranslated leader from the coat protein mRNA of alfalfa mosaic virus (AMV RNA 4) (Jobling et al. (1987) Nature 325:622-625); tobacco mosaic virus leader (TMV) (Gallie et al. (1989) in Molecular Biology of RNA, ed. Cech (Liss, New York), pp. 237-256); and maize chlorotic mottle virus leader (MCMV) (Lommel et al. (1991) Virology 57:382-385). See also, Della-Cioppa et al. (1987) Plant Physiol. 54:965-968. Other methods known to enhance translation can also be utilized, for example, introns, and the like. In preparing the expression cassette, the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as appropriate, in the proper reading frame. Toward this end, adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like. For this purpose, in vitro mutagenesis, primer repair, restriction, annealing, resubstitutions, e.g., transitions and transversions, may be involved. In the same manner, a plant can be transformed with the nucleotide sequences of the invention to provide complete detoxification of fumonisin in the transformed plant and plant products. Such plants include, for example, species from the genera Cucurbita, Rosa, Vitis, Juglans, Fragaria, Lotus, Medicago, Onobrychis, Trifolium, Trigonella, Vigna, Citrus, Linum, Geranium, Manihot, Daucus, Arabidopsis, Brassica, Raphanus, Sinapis, Atropa, Capsicum, Datura, Hyoscyamus, Lycopersicon, Nicotiana, Solanum, Petunia, Digitalis, Majorana, Ciahorium, Helianthus, Lactuca, Bromus, Asparagus, Antirrhinum, Heterocallis, Nemesis, Pelargonium, Panieum, Pennisetum, Ranunculus, Senecio, Salpiglossis, Cucumis, Browaalia, Glycine, Pisum, Phaseolus, Lolium, Oryza, Zea, Avena, Hordeum, Secale, Triticum, Sorghum, Picea, Caco, and Populus. As used herein, "transgenic plant" includes reference to a plant that comprises within its genome a heterologous polynucleotide. Generally, the heterologous polynucleotide is stably integrated within the genome such that the polynucleotide is passed on to successive generations. The heterologous polynucleotide may be integrated into the genome alone or as part of a recombinant expression cassette. "Transgenic" is used herein to include any cell, cell line, callus, tissue, plant part or plant, the genotype of which has been altered by the presence of heterologous nucleic acid including those transgenics initially so altered as well as those created by sexual crosses or asexual propagation from the initial transgenic. The term "transgenic" as used herein does not encompass the alteration of the genome (chromosomal or extra- chromosomal) by conventional plant breeding methods or by naturally occurring events such as random cross-fertilization, nonrecombinant viral infection, nonrecombinant bacterial transformation, nonrecombinant transposition, or spontaneous mutation. The sequences of the present invention can be used to transform or transfect any plant. In this manner, genetically modified plants, plant cells, plant tissue, seed, and the like can be obtained. Transformation protocols as well as protocols for introducing nucleotide sequences into plants may vary depending on the type of plant or plant cell, i.e., monocot or dicot, targeted for transformation. Suitable methods of introducing nucleotide sequences into plant cells and subsequent insertion into the plant genome include microinjection (Crossway et al. (1986) Biotechniques 4:320-334), electroporation (Riggs et al. (1986) Proc. Natl. Acad. Sci. USA 53:5602-5606, Agrobacterium- ediated transformation (Townsend et αl., U.S. Pat No. 5,563,055), direct gene transfer (Paszkowski et αl. (1984) EMBO J. 3:2717-2722), and ballistic particle acceleration (see, for example, Sanford et αl., U.S. Patent No. 4,945,050; Tomes et αl. (1995) "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment," in Plant Cell, Tissue, and Organ Culture: Fundamental Methods, ed. Gamborg and Phillips (Springer- Verlag, Berlin); and McCabe et al. (1988) Biotechnology f5:923-926). Also see Weissinger et al. (1988) Ann. Rev. Genet. 22:421-477; Sanford et al. (1987) Particulate Science and Technology 5:27-37 (onion); Christou et al. (1988) Plant Physiol. 57:671-674 (soybean); McCabe et al. (1988) Bio/Technology (5:923-926 (soybean); Finer and McMullen (1991) In Vitro Cell Dev. Biol. 27P:175-182 (soybean); Singh et al. (1998) Theor. Appl Genet. 96:3X9-324 (soybean); Datta et al. (1990) Biotechnology 5:736-740 (rice); Klein et al. (1988) Proc. Natl. Acad. Sci. USA 55:4305-4309 (maize); Klein et al. (1988) Biotechnology (5:559-563 (maize); Tomes, U.S. Patent No. 5,240,855; Buising et al ., U.S. Patent Nos. 5,322,783 and 5,324,646; Tomes et al. (1995) "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment," in Plant Cell, Tissue, and Organ Culture: Fundamental Methods, ed. Gamborg (Springer-Verlag, Berlin) (maize); Klein et al. (1988) Plant Physiol. 97:440-444 (maize); Fromm et al. (1990) Biotechnology 5:833-839 (maize); Hooykaas-Van Slogteren et al. (1984) Nature (London) 311:763-764; Bowen et al, U.S. Patent No. 5,736,369 (cereals); Bytebier et al. (1987) Proc. Natl. Acad. Sci. USA 54:5345-5349 (Liliaceae); De Wet et al. (1985) in The Experimental Manipulation of Ovule Tissues, ed. Chapman et al. (Longman, New York), pp. 197-209 (pollen); Kaeppler et al. (1990) Plant Cell Reports 9:415-418 and Kaeppler et al. (1992) Theor. Appl. Genet. 54:560-566 (whisker-mediated transformation); D'Halluin et al. (1992) Plant Cell 4:1495-1505 (electroporation); Li et al. (1993) Plant Cell Reports 72:250-255 and Christou and Ford (1995) Annals of Botany 75 :407-413 (rice); Osjoda et al. (1996) Nature Biotechnology 74:745-750 (maize via Agrobacterium tumefaciens); all of which are herein incorporated by reference. The modified plant may be grown into plants in accordance with conventional ways. See, for example, McCormick et al. (1986) Plant Cell. Reports 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that the subject phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure the desired phenotype or other property has been achieved. The degradative enzymes can be fermented in a bacterial host and the resulting bacteria processed and used as a microbial spray. Any suitable microorganism can be used for this purpose. See, for example, Gaertner et al. (1993) in Advanced Engineered Pesticides, Kim (Ed.). The genes of the invention can be introduced into microorganisms that multiply in plants (epiphytes) to deliver enzymes to potential target crops. Epiphytes can be gram-positive or gram-negative bacteria, or fungi, for example. The microorganisms that have been genetically altered to contain at least one degradative gene and protein may be used for protecting agricultural crops and products. In one aspect of the invention, whole, i.e., unlysed, cells of the transformed organism are treated with reagents that prolong the activity of the enzyme produced in the cell when the cell is applied to the environment of a target plant. A secretion signal sequence may be used in combination with the gene of interest such that the resulting enzyme is secreted outside the host cell for presentation to the target plant. It may be preferable to provide for secretion of certain of the enzymes while providing for others to remain in the cytoplasm or targeted to organelles such as, for example, the chloroplast. Generally, the first two gene products, the carboxylesterase and the flavin amine oxidase will be secreted. Secretion leaders are known in the art. Plant signal sequences, including, but not limited to, signal-peptide encoding DNA/RNA sequences which target proteins to the extracellular matrix of the plant cell (Dratewka-Kos et al, (1989) J Biol. Chem. 264:4896-4900), the Nicotiana plumbaginifolia extension gene (DeLoose, et al. (1991) Gene 99:95-100), signal peptides which target proteins to the vacuole like the sweet potato sporamin gene (Matsuka et al. (1991) PNAS 88:834) and the barley lectin gene (Wilkins et al. (1990) Plant Cell 2:301-313), signal peptides which cause proteins to be secreted such as that of PRIb (Lind et al. (1992) Plant Mol. Biol. 18:47-53), or the barley alpha amylase (BAA) (Rahmatullah et al. (1989) Plant Mol. Biol. 12:119) and hereby incorporated by reference, or from the present invention the signal peptide from the ESP1 or BEST1 gene, or signal peptides which target proteins to the plastids such as that of rapeseed enoyl-Acp reductase (Verwaert et al. (1994) Plant Mol. Biol. 26:189-202) are useful in the invention. Such secretion signal sequences can be used in expression cassettes to provide for secretion of the protein of interest outside the cell. The remaining gene products are provided in the cell. These enzymes include a flavin monooxygenase, an aldehyde dehydrogenase and an alcohol dehydrogenase. The expression cassettes for the corresponding genes may contain an organellar targeting sequence. In plants, for example, a chloroplast targeting sequence may be used. In this manner, at least one of the genes encoding a fumonisin- degradation enzyme of the invention may be introduced via a suitable vector into a microbial host, and said transformed host applied to the environment or plants or animals. Microorganism hosts that are known to occupy the "phytosphere" (phylloplane, phyllosphere, rhizosphere, and/or rhizoplane) of one or more crops of interest may be selected for transformation. These microorganisms are selected so as to be capable of successfully competing in the particular environment with the wild-type microorganisms, to provide for stable maintenance and expression of the gene expressing the polypeptide, and, desirably, to provide for improved protection of the enzymes of the invention from environmental degradation and inactivation. Such microorganisms include bacteria, algae, and fungi. Of particular interest are microorganisms, such as bacteria, e.g., Pseudomonas, Erwinia, Serratia, Klebsiella, Xanthomonas, Streptomyces, Rhizobium, Rhodopseudomonas, Methylius, Agrobacterium, Acetobacter, Lactobacillus, Arthrobacter, Azotobacter, Leuconostoc, and Alcaligenes; fungi, particularly yeast, e.g., Saccharomyces, Pichia, Cryptococcus, Kluyveromyces, Sporobolomyces, Rhodotorula, and Aureobasidium. Of particular interest are such phytosphere bacterial species as Pseudomonas syringae, Pseudomonas fluorescens, Serratia marcescens, Acetobacter xylinum, Agrobacteria, Rhodopseudomonas spheroides, Xanthomonas campestris, Rhizobium melioti, Alcaligenes entrophus, Clavibacter xyli, and Azotobacter vinlandii; and phytosphere yeast species such as Rhodotorula rubra, R. glutinis, R. marina, R. aurantiaca, Cryptococcus albidus, C. diffluens, C laurentii, Saccharomyces rosei, S. pretoriensis, S. cerevisiae, Sporobolomyces rosues, S. odorus, Kluyveromyces veronae, and Aureobasidium pullulans. Illustrative prokaryotes, both Gram-negative and -positive, include Enterobacteriaceae, such as Escherichia, Erwinia, Shigella, Salmonella, and Proteus; Bacillaceae; Rhizobiaceae, such as Rhizobium; Spirillaceae, such as photobacterium, Zymomonas, Serratia, Aeromonas, Vibrio, Desulfovibrio, Spirillum; Lactobacillaceae; Pseudomonadaceae, such as Pseudomonas and Acetobacter; Azotobacteraceae; and Nitrobacteraceae. Among eukaryotes are fungi, such as Phycomycetes and Ascomycetes, which includes yeast, such as Saccharomyces and Schizosaccharomyces; and Basidiomycetes yeast, such as Rhodotorula, Aureobasidium, Sporobolomyces, Pichia and the like. Characteristics of particular interest in selecting a host cell for purposes of production include ease of introducing the protein gene into the host, availability of expression systems, efficiency of expression, stability of the protein in the host, and the presence of auxiliary genetic capabilities. Other considerations include ease of formulation and handling, economics, storage stability, fermentation suitability, and the like. A number of ways are available for introducing a gene expressing the degradation enzyme into the microorganism host under conditions that allow for stable maintenance and expression of the gene. For example, expression cassettes can be constructed that include the DNA constructs of interest operably linked with the transcriptional and translational regulatory signals for expression of the DNA constructs, and a DNA sequence homologous with a sequence in the host organism, whereby integration will occur, and/or a replication system that is functional in the host, whereby integration or stable maintenance will occur. Transcriptional and translational regulatory signals include but are not limited to promoter, transcriptional initiation start site, operators, activators, enhancers, other regulatory elements, ribosomal binding sites, an initiation codon, termination signals, and the like. See, for example, U.S. Patent Nos. 5,039,523 and 4,853,331; EPO 0480762A2; Sambrook et al. supra; Maniatis et al., eds. (1982) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York); Davis et al, eds. (1980) Advanced Bacterial Genetics (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York); and the references cited therein. It is recognized that the construction of a catabolic pathway in a transformed organism is a complicated feat. Therefore, any means for assembling the enzymes of interest into an organism of interest is encompassed. For example, a single polynucleotide sequence encoding all of the desired enzymes or multiples thereof may be transformed into the host organism. When microorganisms are to be applied to the environment or to a plant, several microorganisms, each transformed with one, two, three, or more nucleotide sequences of the invention, may be utilized. In this manner, all of the enzymes necessary to bring about detoxification of fumonisin and related products may be presented to the environment or to the plant by applying a mixture of transformed organisms or a single organism capable of expressing the entire pathway or at least expressing enough of the pathway to detoxify fumonisin. In plants, nucleotide sequences for an enzyme may be transformed into a plant and crossed with plants expressing a different enzyme. In this manner, progeny can be obtained having the entire sequence or enough of the sequence to detoxify fumonisin. Alternatively, a plant can be transformed with nucleotides encoding several enzymes at the same time. In some tissue culture systems it is possible to transform callus with one nucleotide sequence, establish a stable culture line, and then transform the callus a second time with a second nucleotide sequence. The process may be repeated to introduce additional sequences. To facilitate the expression of more than one enzyme in a cell, e.g. a plant cell, fusion proteins may be created. Generally, a spacer region is included between the proteins. The spacer region may comprise a cleavage site for cleavage by an endogenous or introduced protease. The present invention also relates to a method of detoxifying a fumonisin or a structurally related mycotoxin with the enzymes from Bacterium 2412.1 during the processing of grain for animal or human food consumption, during the processing of plant material for silage, or food crops contaminated with a toxin-producing microbe, such as but not limited to, tomato. Since the atmospheric ammoniation of corn has proven to be an ineffective method of detoxification (see Haumann (1995) INFORM <5:248-257), such a methodology during processing is particularly critical where transgenic detoxification is not applicable. In this embodiment, the fumonisin degradative enzymes found in Bacterium 2412.1, are presented to grain, plant material for silage, or a contaminated food crop, or during the processing procedure, at the appropriate stages of the procedure and in amounts effective for detoxification of fumonisins and structurally related mycotoxins. Detoxification by this method can occur not only during the processing, but also any time prior to or during the feeding of the grain or plant material to an animal or incorporation of the grain or food crop into a human food product, or before or during ingestion of the food crop. The active ingredients of the present invention are normally applied in the form of compositions and can be applied to the crop area or plant to be treated, simultaneously or in succession, with other compounds. These compounds can be both fertilizers or micronutrient donors or other preparations that influence plant growth. They can also be selective herbicides, insecticides, fungicides, bactericides, nematicides, mollusicides, or mixtures of several of these preparations, if desired, together with further agriculturally acceptable carriers, surfactants, or application-promoting adjuvants customarily employed in the art of formulation. Suitable carriers and adjuvants can be solid or liquid and correspond to the substances ordinarily employed in formulation technology, e.g., natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, binders, or fertilizers. The enzymes can be introduced during processing in appropriate manners, for example as a wash or spray, or in dried or lyophilized form or powered form, depending upon the nature of the milling process and/or the stage of processing at which the enzymatic treatment is carried out. See generally, Hoseney (1990) Principles of Cereal Science and Technology (American Association of Cereal Chemists, Inc.) especially Chapters 5, 6, and 7; Jones (1992) Food Safety (Eagan Press, St. Paul, Minnesota) especially Chapters 7 and 9; and Jelen (1985) Introduction to Food Processing (Restan Publishing Company, Reston, Virginia). Processed grain or silage to be used for animal feed can be treated with an effective amount of the enzymes in the form of an inoculant or probiotic additive, for example, or in any form recognized by those skilled in the art for use in animal feed. The enzymes of the present invention are expected to be particularly useful in detoxification during processing and/or in animal feed prior to its use, since the enzymes display relatively broad ranges of pH activity. The esterase enzymes from Exophiala spinifera, American Type Culture Collection Accession No. 74269, showed a range of activity from about pH 3 to about pH 7 (U.S. Patent No. 5,716,820, supra). The APAO enzyme from Exophiala spinifera, American Type Culture Collection Accession No. 74269 has a pH range of activity from pH 5 to pH 10. While not limited thereto, it is expected that the enzymes of the present invention will exhibit similar activity. In another embodiment, ruminal microorganisms can be genetically engineered to contain and express at least one of the fumonisin degradation enzymes of the invention. The genetic engineering of microorganisms is now an art-recognized technique, and ruminant microorganisms so engineered can be added to feed in any art recognized manner, for example as a probiotic or inoculant. In addition, microorganisms, plants, or other organisms or their cultured cells in vitro capable of functioning as bioreactors can be engineered so as to be capable of mass producing the fumonisin degrading enzymes of the invention. Cite use of Bacterium 2412.1 itself, engineered to express these enzymes constitutively by manipulating regulatory factors, e.g. fccJ (LysR homolog). Another embodiment of the present invention is the use of the enzymes of the present invention as detection reagents for fumonisins and related compounds. The enzymes of the present invention can be used as detection reagents because of the high specificity of the esterase and deaminase enzymes, and the fact that hydrolysis followed by amine oxidation can be monitored by detection of hydrogen peroxide or ammonia using standard reagents (analogous to a glucose detection assay using glucose oxidase). Hydrogen peroxide is often measured by linking a hydrogen peroxide-dependent peroxidase reaction to a colored or otherwise detectable peroxidase product (e.g., Demmano et al. (1996) European Journal of Biochemistry 238(3):785-789). Ammonia can be measured using ion-specific electrodes: Fritsche et al. (1991) Analytica Chimica Ada 244(2):179-182; West et al. (1992) Analytical Chemistry 64(5):533-540, and all herein incorporated by reference) or by GC or other chromatographic method. For example, recombinant or non-recombinant, active fumonisin esterase, APAO, and proteins of the invention are added in catalytic amounts to a sample tube containing an unknown amount of fumonisins (FBI, FB2, FB3, FB4, or partial or complete hydrolysis products of these). The tube is incubated under pH and temperature conditions sufficient to convert any fumonisin in the sample to API, the API to 2-OP, ammonia, and hydrogen peroxide, and to further degradation products. Then suitable reagents are added for quantification of the hydrogen peroxide or ammonia that were generated stoichiometrically from fumonisins. By comparison with control tubes that received no esterase or APAO enzyme, the amount of fumonisin present can be calculated in direct molar proportion to the hydrogen peroxide or ammonia detected, relative to a standard curve. This invention can be better understood by reference to the following nonlimiting examples. It will be appreciated by those skilled in the art that other embodiments of the invention may be practiced without departing from the spirit and the scope of the invention as herein disclosed and claimed. EXPERIMENTAL Example 1 Bacterial isolates Bacterium 2412.1 isolates from maize were isolated as described in U.S. Patent No. 5,716,820 and pending U.S. Application Serial Nos. 08/888,949 and 08/888,950, both filed July 7, 1997, and herein incorporated by reference. Alkaline hydrolysis of FBI to API FBI or crude fumonisin C 8 material was suspended in water at 10-100 mg/ml and added to an equal volume of 4 N NaOH in a screw-cap tube. The tube was sealed and incubated at 60°C for 1 hr. The hydrolysate was cooled to room temperature and mixed with an equal volume of ethyl acetate, centrifuged at 1000 RCF for 5 minute and the organic (upper) layer recovered. The pooled ethyl acetate layers from two successive extractions were dried under N and resuspended in distilled H O. The resulting material (the aminopentol of FBI or "API" was analyzed by TLC. Analysis of fumonisins and metabolism products Analytical thin-layer chromatography was carried out on 100%) silanized Cis silica plates (Sigma #T-7020; 10 x 10 cm; 0.1 mm thick) by a modification of the published method of Rottinghaus (Rottinghaus et al. (1992) J Vet. Diagn. Invest. 4:326, and herein incorporated by reference). To analyze fumonisin esterase activity, sample lanes were pre- wet with methanol to facilitate sample application. After application of from 0.1 to 2 μl of aqueous sample, the plates were air-dried and developed in MeOH:4%> KC1 (3:2) or MeOH:0.2 M KOH (3:2) and then sprayed successively with 0.1 M sodium borate (pH 9.5) and fluorescamine (0.4 mg/ml in acetonitrile). Plates were air-dried and viewed under long- wave UV. For analysis of APAO activity, an alternative method was used. Equal volumes of sample and 14 C-AP1 (1 mg/ml, 50 mM Na-phosphate pH 8) substrate were incubated at room temperature for six days. Analytical thin- layer chromatography was then carried out on C60 HPK silica gel plates (Whatman #4807-700; 10x10 cm; 0.2 mm thick). After application of from 0.1 to 2 μl of aqueous sample, the plates were air dried and developed in CHCl 3 :MeOH:CH 3 COOH:H 2 O (55:36:8:1). Plates were then air dried, and exposed to Phosphorlmager screen or autoradiographic film. A Storm Phosphorlmager was used to scan the image produced on the screen. Example 2 Isolation of Fumonisin-catabolizing Gene Cluster A FBI catabolizing esterase was identified in the culture supernatant of Bacterium 2412.1, and a gene (BacEst) was cloned from this bacterium. The gene exhibited fumonisin esterase activity similar to that of the black yeast esterase ESP1. Since FBI is catabolized to CO 2 in this bacterium, other proteins involved in the breakdown and transport of fumonisin would also be present in induced cells of Bacterium 2412.1. The identification and isolation of a fumonisin detoxification cluster in Bacterium 2412.1 has been accomplished. The BacEst and CTP genes as well as other structural genes and at least 3 regulatory genes have been cloned. Sequence analysis indicates that these genes code for a set of proteins that are involved in the further catabolism and transmembrane transport of fumonisin and its catabolic products (see Table 1 and Figure 1). These proteins provide a catabolic pathway for the degradation of fumonisins, and could also be used to engineer a fumonisin-regulated gene transcription system. In order to identify fumonisin catabolic genes other than bacterial esterase, it was noted that many bacterial pathway genes are clustered together on the bacterial chromosome often containing one or more operons. Both structural and regulatory genes that regulate transcription of individual pathway genes often are found in such clusters. A 4.3 kb genomic fragment from a lambda Zap II phage library, which contained a complete, functional fumonisin esterase gene (BacEst) and in addition a complete open reading frame coding for a citrate transport protein (CTP), predicted to be involved in transport of tricarballylate into the bacterium was cloned. Therefore, approximately 500 bp DNA subclones from the distal ends of this 4.3 kb fragment was used as 32 P- radiolabeled probes to identify additional lambda clones from this portion of the bacterial chromosome (i.e. chromosome "walking"). The probes were designated as P-BacEst (SEQ ID NO: 54) (at the 5' end relative to BacEst direction of transcription), and P-CTP (SEQ ID NO: 55) (at the 3' end). A genomic library used earlier to clone BacEst (Sau3 A partially digested DNA from 2412.1, size selected for 4 to 10 kb insert size, cloned into lambda Zap II from Strategene) was used. A series of overlapping clones was identified by plaque hybridization using both P-BacEST and P-CTP probes together, and these clones were characterized by PCR using combinations of primers from probes and from the vector flanking regions. An overlapping series of clones representing various amounts of sequence extending out from the original 4.3 kb fragment was chosen based on a novel PCR screening method in which phage lysates were subjected to PCR with vector primers and probe-specific primers, in order to gauge the degree of overlap and extension. Phagemids chosen in this way were excised from lambda phage, plasmid DNA prepared from standard plasmid mini-preps and sequenced. For a second round of walking, distal probes (SEQ ID NOS: 56 and 57) were prepared from both ends of the longest 5' and 3' sequence obtained in the first round and library screening was repeated. A lOOmL culture of bacterium 2412.1 was grown to saturation in LB broth and high molecular weight genomic DNA was isolated using standard methods (Short Protocols in Molecular Biology, 2 nd Ed., pp.2-11). The genomic DNA was digested with BamHI and dephosphorylated with Shrimp Alkaline Phosphatase. The SuperCos I Cosmid Vector Kit (Stratagene) was used for library construction. The SCosI vector was digested with Xbal, dephosphorylated with Shrimp Alkaline Phosphatase, then digested with BamHI. The genomic DNA was ligated into the SCosI vector then packaged into XLI-Blue MR E. coli cells. The primary cosmid library was titered at 50 cfu/uL with a total of 30,000 cfu's. Cosmid DNA was prepared from eight colonies and digested with Notl to excise the inserts to estimate insert size. Average insert size was 27kb with a range of 17.5-35kb. The primary library was amplified and titered at 2x10 cfu/mL. Probes were made from the ends of the current BAM gene cluster and designated SCos_5' (SEQ ID NO: 58) and SCos_3' (SEQ ID NO: 59). The library was screened with 50,000 cfu's/plate using the SCos_5' probe and yielded 35 clones which hybridized to the SCos_5' probe. Inserts from these clones were excised using Notl which also produced smaller fragments of DNA from each clone. The fragments were then subcloned into the pSPORTI vector (GibcoBRL) that was previously digested with Notl and dephosphorylated. The pSPORTI fragments were transformed into E. coli DH5a cells, DNA was miniprepped and digested with Notl to verify subclones with the correct inserts. The subclones were then sequenced with M13F and M13R primers to obtain DNA sequence from the ends of each subclone. Primer- walking was then used to fully sequence each subclone. The 8.5kb subclone contigged with the 5' end of the BAM gene cluster. The individual lambda clones and cosmids were sequenced to the point of overlap, and a single large contig assembled from the various clones (Figure 2). Table II summarizes the American Type Culture Collection deposits made containing the overlapping clones of the fumonisin catabolic gene cluster. The strain designation and their corresponding plasmids are provided. TABLE 2 The contig represents 24.5 kb of chromosomal DNA, and contains twenty open reading frames including the fumonisin esterase and citrate transport homolog. Most of the genes in this region have homology to genes known to function in carbon catabolic pathways that involve functional groups that would be expected to be utilized for fumonisin. These have been given appropriate designations as fccA through fccT (fumonisin catabolic cluster) (Table 1). One open reading frame, fccJ, has homology to negative regulatory genes controlling lysine degradation pathway (LysR) and could be the regulator that prevents transcription of genes in this cluster in the absence of substrate. Other open reading frames in this region may be involved in other cellular functions needed for effective catabolism of fumonisin. A map of the open reading frames in the fumonisin catabolic gene cluster of Bacterium 2412.1 is shown in Figure 3. Many of the gene functions deduced from ORFs in this cluster have also been identified among API -induced transcripts from Exophiala spinifera (see U.S. Application Nos. 08/888,949; 08/888,950; and Table 2). These are, aside from the fumonisin esterase: flavin monooxygenase, aldehyde dehydrogenase, alcohol dehydrogenase, and transmembrane permease. A possible degradation pathway for fumonisins based on these enzyme activities is presented in Figure 1. The functional similarity of bacterial fee cluster genes and AP 1 -induced Exophiala cDNAs increases the likelihood that these genes are involved in fumonisin breakdown in the respective organisms. To identify an open reading frame corresponding to a deaminating enzyme such as the API -specific amine oxidase identified as an induced transcript in E. spinifera (APAO) cosmid clones corresponding to flanking regions of the fee cluster have been obtained. It is anticipated such a gene will be found in this flanking DNA. However, identification of this gene is not crucial to this invention, as we have demonstrated API deaminating activity of the Exophiala spinifera cDNA for APAO in a bacterial expression system, so it is possible to engineer the fungal gene along with bacterial genes in this cluster to engineer a complete pathway. cDNA sequences for a citrate/tricarballylate transport protein (fccB) (SEQ ID NO: 4); a flavin monooxygenase (fccC) (SEQ ID NO: 6); an aldehyde dehydrogenase (fccD) (SEQ ID NO: 8); an alcohol dehydrogenase (fccE) (SEQ ID NO: 10); a CoA ligase (fccF) (SEQ ID NO: 12); an acetohydroxyacid synthase (fccG) (SEQ ID NO: 14); a vitamin B12 receptor (fccH) (SEQ ID NO: 16); a permease (feel) (SEQ ID NO: 18); and a regulatory protein (fccJ) (SEQ ID NO: 20); a fumarate reductase/aspartate oxidase (fccK) (SEQ ID NO: 22); a TonB dependent receptor (fccL) (SEQ ID NO: 24); a protein with homology to N-methyl transferase (fccM) (SEQ ID NO: 26); a citrate utilization B (fccN) (SEQ ID NO: 28); a carbohydrate regulatory gene (fccO) (SEQ ID NO: 30); a possible flavoenzyme (fccP) (SEQ ID NO: 32); a leucine regulator}' protein homolog (fccQ) (SEQ ID NO: 34); fccR (SEQ ID NO:36); fccS (SEQ ID NO: 38); fccT (SEQ ID NO: 40) have been isolated. Such sequences are provided. An esterase (fccA) also known as BacEst has previously been described. The complete 24.5 kb contig of SEQ ID NO:l is likely to code for all the regulatory, transport, and catabolic machinery needed to catabolize FBI to nontoxic metabolites. A single full-length cosmid clone that contains all of these genes together in order to test this hypothesis. This can readily be done by screening a cosmid library with probes generated from sequence on both ends of the contig, and selecting clones that hybridized under stringent conditions to both probes. The cosmid-containing E coli strain would then be evaluated for its ability to break down fumonisin or API added to the culture medium. Example 3 Pichia Expression of Degradative Enzymes For cloning into Pichia pastor is expression vector, pPicZalphaA, oligonucleotide primers can be designed that contain a 22 bp overlap of the 5' end (sense strand) and 3' end (antisense strand), respectively of the open reading frame from Bacterium 2412.1, including the stop codon. In addition, each oligo has a 5' extension with digestible restriction sites that allows cloning of the amplified insert in-frame both into EcoRI/Notl digested pPicZalphaA. pPicZalphaA is an E. coli compatible Pichia expression vector containing a functional yeast alpha factor secretion signal and peptide processing sites, allowing high efficiency, inducible secretion into the culture medium of Pichia. Pichia can be transformed as described in Invitrogen Manual, Easy Select™ Pichia Expression Kit, Version B, #161219, with the enzyme polynucleotide of interest with either an intron added (negative control, no expression) or an intron not added (capable of making an active protein). The Pichia culture fluids and pellets are assayed for enzyme activity as described earlier. The sample 50 UL cell pellets are resuspended in 150 UL cold 50mM Na-phosphate, pH8.0 and divided into two fresh 500 UL tubes. One tube is kept on ice with no treatment, the pellet suspension, and one tube is used for lysis. An equal volume of 0.1 mm zirconia-silica beads is added to each tube. The tubes are BeadBeat™ for 15 seconds then cooled on ice 5 minutes. This is repeated three times. The crude lysate is then transferred to another tube for assay or lysate suspension. The TLC assays are performed as follows: - samples: 1.) pellet suspensions ("PELL"); 10 uL 2.) lysate suspensions ("LYS"); 10 uL 3.) media controls-mixed 5 uL media with 5 uL crude bacterial enzyme (if available); 10 uL 4.) positive control-used crude bacterial enzyme (if available) undiluted; 10 uL 5.) substrate control-used 50mM Na-phosphate, pH8.0; 10 uL - a cofactor (if required) is added to each reaction mixture - incubate 10 uL each sample + 10 uL 14 C-substrate (fumonisin, metabolite, or other potential substrate) (1 mg/mL, pH8) at room temperature - spot 1.0 uL onto C 18 and C60 TLC plates - develop C18 plates in MeOH:4% KC1 (3:2) - develop C60 plates in CHCl 3 :MeOH:CH 3 COOH:H 2 O (55:36:8:1) - air-dry plates - expose plates to PhosphorScreen 2-3 days - use Storm Phosphorlmager (Molecular Dynamics) to develop images Example 4 Expression of Enzymes in E. coli The vector for expressing the enzyme of interest is a prokaryotic glutathione S-transferase (GST) fusion vector for inducible, high-level intracellular expression of genes or gene fragments as fusions with Schistosoma japonicum GST. GST gene fusion vectors include the following features: a lac promoter for inducible, high-level expression; an internal lac I q gene for use in any E. coli host; and the thrombin factor Xa or PreScission Protease recognition sites for cleaving the desired protein from the fusion product. The insert of interest may be cloned into the 5' EcoRI site and a 3' Notl site allowing in- frame expression of the fusion peptide. Generation of such an insert is described in the previous example. E. coli was transformed with the vector containing the coding sequence for the enzyme as described in BRL catalogue, Life Technologies, Inc., catalogue; Hanahan (1983) J. Mol. Biol. 166:557; Jessee et al. (1984) J Focus 6:4; King et al. (1986) Focus 5:1, and hereby incorporated by reference. The transformed E. coli may be induced by addition of IPTG (isopropyl b-D- thiogalactopyranoside) for expression of the polypeptide of interest. Example 5 Transformation and Regeneration of Transgenic Plants Immature maize embryos from greenhouse donor plants are bombarded with a plasmid containing the fumonisin-degradation/transporter enzyme nucleotide sequences operably linked to a ubiquitin promoter (Figure 4). This plasmid also contains the selectable marker gene PAT (Wohlleben et al. (1988) Gene 70:25-37) that confers resistance to the herbicide Bialaphos. The preferred construct for expression in maize is the nucleotide sequence of the degradative enzyme either fused to the barley alpha amylase signal sequence or organellar targeting sequence, or left intact for expression in the cytoplasm. Transformation is performed as follows. All media recipes are in the Appendix. Preparation of Target Tissue The ears are surface sterilized in 30%> Chlorox bleach plus 0.5% Micro detergent for 20 minutes, and rinsed two times with sterile water. The immature embryos are excised and placed embryo axis side down (scutellum side up), 25 embryos per plate, on 560Y medium for 4 hours and then aligned within the 2.5-cm target zone in preparation for bombardment. Preparation of DNA A plasmid vector comprising the fumonisin-degradation transporter enzyme operably linked to the ubiquitin promoter is made. This plasmid DNA also contains a PAT selectable marker. The plasmid is precipitated onto 1.1 μm (average diameter) tungsten pellets using a CaCl precipitation procedure as follows: 100 μl prepared tungsten particles in water 10 μl (1 μg) DNA in TrisEDTA buffer (1 μg total) 100 μl 2.5 M CaCl 2 10 μl 0.1 M spermidine Each reagent is added sequentially to the tungsten particle suspension, while maintained on the multitube vortexer. The final mixture is sonicated briefly and allowed to incubate under constant vortexing for 10 minutes. After the precipitation period, the tubes are centrifuged briefly, liquid removed, washed with 500 ml 100%) ethanol, and centrifuged for 30 seconds. Again the liquid is removed, and 105 μl 100%) ethanol is added to the final tungsten particle pellet. For particle gun bombardment, the tungsten/DNA particles are briefly sonicated and 10 μl spotted onto the center of each macrocarrier and allowed to dry about 2 minutes before bombardment. Particle Gun Treatment The sample plates are bombarded at level #4 in particle gun #HE34-1 or #HE34-2. All samples receive a single shot at 650 PSI, with a total often aliquots taken from each tube of prepared particles/DNA. Subsequent Treatment Following bombardment, the embryos are kept on 560Y medium for 2 days, then transferred to 560R selection medium containing 3 mg/liter Bialaphos, and subcultured every 2 weeks. After approximately 10 weeks of selection, selection-resistant callus clones are transferred to 288J medium to initiate plant regeneration. Following somatic embryo maturation (2-4 weeks), well-developed somatic embryos are transferred to medium for germination and transferred to the lighted culture room. Approximately 7-10 days later, developing plantlets are transferred to 272V hormone-free medium in tubes for 7-10 days until plantlets are well established. Plants are then transferred to inserts in flats (equivalent to 2.5" pot) containing potting soil and grown for 1 week in a growth chamber, subsequently grown an additional 1 -2 weeks in the greenhouse, then transferred to classic 600 pots (1.6 gallon) and grown to maturity. Plants are monitored for the expression of a fumonisin- degrading/transporter protein. APPENDIX 272 V Directions: @ = Add after bringing up to volume Dissolve ingredients in polished D-I H O in sequence Adjust to pH 5.6 Bring up to volume with polished D-I H O after adjusting pH Sterilize and cool to 60°C. ## = Dissolve 0.100 g of Nicotinic Acid; 0.020 g of Thiamine.HCL; 0.100 g of Pyridoxine.HCL; and 0.400 g of Glycine in 875.00 ml of polished D-I H 2 O in sequence. Bring up to volume with polished D-I H 2 O. Make in 400 ml portions. Thiamine.HCL & Pyridoxine.HCL are in Dark Desiccator. Store for one month, unless contamination or precipitation occurs, then make fresh stock. Total Volume (L) = 1.00 288 J Directions: @ = Add after bringing up to volume Dissolve ingredients in polished D-I H 2 O in sequence Adjust to pH 5.6 Bring up to volume with polished D-I H 2 O after adjusting pH Sterilize and cool to 60°C. Add 3.5g/L of Gelrite for cell biology. ## = Dissolve 0.100 g of Nicotinic Acid; 0.020 g of Thiamine.HCL; 0.100 g of Pyridoxine.HCL; and 0.400 g of Glycine in 875.00 ml of polished D-I H 2 O in sequence. Bring up to volume with polished D-I H 2 O. Make in 400 ml portions. Thiamine.HCL & Pyridoxine.HCL are in Dark Desiccator. Store for one month, unless contamination or precipitation occurs, then make fresh stock. Total Volume (L) = 1.00 560 R Directions: @ = Add after bringing up to volume # = Add after sterilizing and cooling to temp. Dissolve ingredients in D-I H O in sequence Adjust to pH 5.8 with KOH Bring up to volume with D-I H 2 O Sterilize and cool to room temp. Total Volume (L) = 1.00 560 Y Directions: @ = Add after bringing up to volume # = Add after sterilizing and cooling to temp. Dissolve ingredients in D-I H O in sequence Adjust to pH 5.8 with KOH Bring up to volume with D-I H O Sterilize and cool to room temp. ** Autoclave less time because of increased sucrose** Total Volume (L) = 1.00 All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims. Applicant's or agent's International application No file reference 5718-62-1 PCT/US99/ INDICATIONS RELATING TO DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13/Ms) The indications made below relate to the deposited microorganism or other biological material referred to in the description on page 5, lines 5, 13 and 17 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet |~ Name of depository institution American Type Culture Collection Address of depositary institution (including postal code and country) 10801 University Blvd. Manassas. VA 20110-2209 USA Date of deposit Accession Number 28 June 1998 (28.06.98) PTA-298; PTA-296; PTA-297 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet [~J D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indicators are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e g , "Accession Number of Deposit") For receiving Office use only For International Bureau use only □ This sheet was received with the international application CTJ This sheet was received with the International Bureau on Authorized officer Authorized officer Form PCT/RO/134 (July 1998) 56/1

Claims: THAT WHICH IS CLAIMED: 1. An isolated nucleotide sequence encoding a fumonisin degradative enzyme or transporter from Bacterium 2412.1 , said nucleotide sequence is selected from the group consisting of; a) a nucleic acid molecule that encodes a regulatory protein, a flavin monooxygenase, an aldehyde dehydrogenase, an alcohol dehydrogenase, a permease, a Co A ligase, an acetohydroxyacid synthase, a vitamin B12 receptor, and a citrate transport protein, a fumarate reductase/aspartate oxidase, a TonB dependent receptor, an N-methyl transferase, a carbohydrate regulatory protein, a flavoenyzme, a citrate utilization B protein, and a leucine responsive regulatory protein; b) a nucleic acid molecule that encodes fccR, fccS, and fccT; c) a nucleic acid molecule that encodes the amino acid sequences set forth in SEQ ID NOS: 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, and 41; d) a nucleic acid molecule set forth in SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40; e) a nucleic acid molecule comprising at least 20 contiguous nucleotides of a nucleotide sequences of a), b), c) or d); f) a nucleic acid molecule having at least 40%o identity to a nucleotide sequences of a), b), c), or d); g) a nucleic acid molecule that hybridizes under stringent conditions to the sequence of a), b), c) or d); h) a nucleic acid molecule having 20 contiguous nucleotides that hybridizes under stringent conditions to the sequences of a), b), c) or d). 2. An expression cassette comprising a nucleotide sequence of claim 1, wherein said nucleotide sequence is operably linked to a promoter that drives expression in a plant cell. 3. An expression cassette comprising a nucleotide sequence of 57 claim 1 , wherein said nucleotide sequence is operably linked to a promoter that drives expression in a microorganism. 4. The expression cassette of claims 2 or 3, wherein said promoter is a constitutive promoter. 5. A vector for delivery of a nucleotide sequence to a host cell, the vector comprising at least one nucleotide sequence of claim 1. 6. A host cell containing the vector of claim 5. 7. A host cell comprising in its genome at least one nucleotide sequence of claim 1. 8. The host cell of claim 7, wherein the plant is selected from the group consisting of maize, sorghum, wheat, tomato, soybean, alfalfa, sunflower, Brassica, cotton, and rice. 9. A transformed plant cell having incorporated into its genome at least one of the nucleotide sequences of claim 1. 10. A transformed plant having incorporated into its genome at least one of the nucleotide sequences of claim 1. 11. Seed of the plant of claim 10. 12. A plant having stably incorporated within its genome a nucleotide sequence encoding a fumonisin degradative enzyme or transporter from Bacterium 2412.1, said nucleotide sequence selected from the group consisting of: a) a nucleic acid molecule that encodes a regulatory protein, a flavin monooxygenase, an aldehyde dehydrogenase, an alcohol dehydrogenase, a permease, a CoA ligase, an acetohydroxyacid synthase, a 58 vitamin B 12 receptor, and a citrate transport protein, a fumarate reductase/aspartate oxidase, a TonB dependent receptor, an N-methyl transferase, a carbohydrate regulatory protein, a flavoenyzme, a citrate utilization B protein, and a leucine responsive regulatory protein; b) a nucleic acid molecule that encodes fccR, fccS, and fccT; c) a nucleic acid molecule that encodes the amino acid sequences set forth in SEQ ID NOS: 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, and 41; d) a nucleic acid molecule set forth in SEQ ID NOS : 1 , 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40; e) a nucleic acid molecule comprising at least 20 contiguous nucleotides of a nucleotide sequences of a), b), c), or d); f) a nucleic acid molecule having at least 40%> identity to a nucleotide sequences of a), b), c), or d); g) a nucleic acid molecule that hybridizes under stringent conditions to the sequence of a), b), c) or d). 13. A method of reducing pathogenicity of a fungus producing fumonisin, comprising: a) transforming a plant cell with a vector comprising a nucleotide sequence encoding a fumonisin enzyme from Bacterium 2412.1 operably linked to a promoter, wherein said nucleotide sequence is selected from the group consisting of: i) a nucleic acid molecule that encodes a regulatory protein, a flavin monooxygenase, an aldehyde dehydrogenase, an alcohol dehydrogenase, a permease, a CoA ligase, an acetohydroxyacid synthase, a vitamin B12 receptor, and a citrate transport protein, a fumarate reductase/aspartate oxidase, a TonB dependent receptor, an N-methyl transferase, a carbohydrate regulatory protein, a flavoenyzme, a citrate utilization B protein, and a leucine responsive regulatory protein; ii) a nucleic acid molecule that encodes fccR, fccS, and fccT; 59 iii) a nucleic acid molecule that encodes the amino acid sequences set forth in SEQ ID NOS: 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, and 41; iv) a nucleic acid molecule set forth in SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40; v) a nucleic acid molecule comprising at least 20 contiguous nucleotides of a nucleotide sequences of i), ii), iii) or iv); vi) a nucleic acid molecule having at least 40% identity to a nucleotide sequences of i), ii), iii) or iv); vii) a nucleic acid molecule that hybridizes under stringent conditions to the sequence of i), ii), iii), or iv); viii) a nucleic acid molecule having 20 contiguous nucleotides that hybridizes under stringent conditions to the sequences of i), ii), iii), or iv); b) growing the plant cell under growing conditions; and c) inducing expression of said nucleotide sequence for a time sufficient for amounts of the enzyme to accumulate to levels that can reduce pathogenicity of said fungus. 14. The method of claim 13, wherein said plant cell further comprises at least one enzyme selected from a carboxylesterase or a flavin amine oxidase. 15. A plant capable of degrading or transporting fumonisin, said plant having stably incorporated within its genome at least one nucleotide sequence coding for a fumonisin enzyme from Bacterium 2412.1 operably linked to a plant promoter, wherein said nucleotide sequence is selected from the group consisting of: a) a nucleic acid molecule that encodes a regulatory protein, a flavin monooxygenase, an aldehyde dehydrogenase, an alcohol dehydrogenase, a permease, a CoA ligase, an acetohydroxyacid synthase, a vitamin B 12 receptor, and a citrate transport protein, a fumarate reductase/aspartate oxidase, a TonB dependent receptor, an N-methyl 60 transferase, a carbohydrate regulatory protein, a flavoenyzme, a citrate utilization B protein, and a leucine responsive regulatory protein; b) a nucleic acid molecule that encodes fccR, fccS, and fccT; c) a nucleic acid molecule that encodes the amino acid sequences set forth in SEQ ID NOS: 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, and 41; d) a nucleic acid molecule set forth in SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40; e) a nucleic acid molecule comprising at least 20 contiguous nucleotides of a nucleotide sequences of a), b), c), or d); f) a nucleic acid molecule having at least 40%> identity to a nucleotide sequences of a), b), c) or d); g) a nucleic acid molecule that hybridizes under stringent conditions to the sequence of a), b), c) or d); h) a nucleic acid molecule having 20 contiguous nucleotides that hybridizes under stringent conditions to the sequences of a), b), c) or d). 16. The plant of claim 15, wherein said plant has stably incorporated within its genome nucleotide sequences consisting of at least two nucleotide sequences for a fumonisin degradative enzyme. 17. The plant of claim 15, wherein at least one nucleotide sequence encodes a carboxylesterase or a flavin amine oxidase. 18. The plant of claim 15, wherein said plant is selected from the group consisting of maize, sorghum, wheat, tomato, soybean, alfalfa, sunflower, Brassica, cotton, and rice. 19. A method of detoxifying a fumonisin, or a structurally related mycotoxin, comprising applying at least one fumonisin degradative enzyme from Bacterium 2412.1, wherein said enzyme is encoded by a nucleic acid sequence selected from the group consisting of : 61 a) a nucleic acid molecule that encodes a regulatory protein, a flavin monooxygenase, an aldehyde dehydrogenase, an alcohol dehydrogenase, a permease, a CoA ligase, an acetohydroxyacid synthase, a vitamin B12 receptor, and a citrate transport protein, a fumarate reductase/aspartate oxidase, a TonB dependent receptor, an N-methyl transferase, a carbohydrate regulatory protein, a flavoenyzme, a citrate utilization B protein, and a leucine responsive regulatory protein; b) a nucleic acid molecule that encodes fccR, fccS, and fccT; c) a nucleic acid molecule that encodes the amino acid sequences set forth in SEQ ID NOS: 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, and 41; d) a nucleic acid molecule set forth in SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40; e) a nucleic acid molecule comprising at least 20 contiguous nucleotides of a nucleotide sequences of a), b), or c); f) a nucleic acid molecule having at least 40% identity to a nucleotide sequences of a), b), c), or d); g) a nucleic acid molecule that hybridizes under stringent conditions to the sequence of a), b), c) or d); h) a nucleic acid molecule having 20 contiguous nucleotides that hybridizes under stringent conditions to the sequences of a), b), c) or d). 20. The method of claim 19, wherein the fumonisin or structurally related mycotoxin is present in harvested grain. 21. The method of claim 19, wherein said detoxification occurs during processing of harvested grain. 22. The method of claim 19, wherein said detoxification occurs in processed grain which is to be used as animal feed. 23. The method of claim 19, wherein detoxification occurs in silage. 62 24. A method of making an enzyme useful in degrading fumonisin, said method comprising: a) expressing a nucleotide sequence of claim 1 in a recombinantly engineered cell; and b) purifying the enzyme. 25. A method of making an enzyme useful in degrading fumonisin, said method comprising: a) expressing a nucleotide sequence of claim 1 in a plant; and b) purifying the enzyme from the plant seed or other plant parts. 26. A genetically engineered ruminal microorganism comprising at least one nucleotide sequence of claim 1. 27. A probiotic composition comprising the genetically engineered ruminal organism of claim 26. 28. A feed inoculant composition comprising the genetically engineered ruminal microorganism of claim 26. 29. An isolated nucleotide sequence, said nucleotide sequence selected from the group consisting of : a) a nucleotide sequence encoding a bacterial fumonisin- catabolizing gene cluster; b) a sequence from Bacterium 2412.1 set forth in SEQ ID NO: 1; c) a nucleotide sequence obtained from the overlapping clones deposited with the American Type Culture Collection as Accession Numbers PTA-298, PTA-296, and PTA-297; d) an isolated nucleotide sequence that hybridizes under 63 stringent conditions to the sequences of a), b) or c). 30. A host cell transformed with the sequence of claim 29. 31. The host cell of claim 30, wherein said host cell is a bacterium, a yeast, or a plant host cell. 64

Inventors: DUVICK JONATHAN P, GILLIAM JACOB, MADDOX JOYCE, DUVICK, JONATHAN, P., GILLIAM, JACOB, MADDOX, JOYCE
Applicants: DUVICK JONATHAN P, GILLIAM JACOB, MADDOX JOYCE, PIONEER HI BRED INT, DUVICK, JONATHAN, P., GILLIAM, JACOB, MADDOX, JOYCE, PIONEER HI-BRED INTERNATIONAL, INC.
Application year: 1999
Main classification: C12N15
IPC codes: A23K1, A23K3, C12N1, C12N15